ReviewBMC infectious diseases2015
How to treat fungal infections in ICU patients.
Review in BMC infectious diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 36 citations in OpenAlex.
- Article
- Breaking barriers in Candida spp. detection with Electronic Noses and artificial intelligence.Scientific reports · 2024Article
- Invasive Pulmonary Aspergillosis: Not Only a Disease Affecting Immunosuppressed Patients.Diagnostics (Basel, Switzerland) · 2023Article
- Suboptimal plasma concentrations with posaconazole suspension as prophylaxis in critically ill COVID-19 patients at risk of Covid-associated pulmonary aspergillosis.Journal of clinical pharmacy and therapeutics · 2022Article
- Retrospective Evaluation of Risk Factors for InvasiveInfectious diseases & clinical microbiology · 2022Article
- Targeted Delivery of Miconazole Employing LL37 Fragment Mutant Peptide CKR12-Poly (Lactic-Co-Glycolic) Acid Polymeric Micelles.International journal of molecular sciences · 2021Article
- Dynamic Risk Prediction for Hospital-Acquired Pressure Injury in Adult Critical Care Patients.Critical care explorations · 2021Article
- In vitro study on the potential fungicidal effects of atorvastatin in combination with some azole drugs against multidrug resistant Candida albicans.World journal of microbiology & biotechnology · 2021Article
- In Vitro Antifungal Activity and Mechanism of AgMolecules (Basel, Switzerland) · 2020Article
- Alteration of Fermentative Metabolism Enhances Mucor circinelloides Virulence.Infection and immunity · 2020Article
- In Vitro Anticandidal Activity and Mechanism of a Polyoxovanadate Functionalized by Zn-Fluconazole Complexes.Molecules (Basel, Switzerland) · 2018Article
- Epidemiology of sepsis in intensive care units in Turkey: a multicenter, point-prevalence study.Critical care (London, England) · 2018Article
- Review
- An Immunomodulatory Peptide Confers Protection in an Experimental Candidemia Murine Model.Antimicrobial agents and chemotherapy · 2017Article
- Encapsulation of Antifungals in Micelles ProtectsFrontiers in microbiology · 2017Article
- Synthetic Organotellurium Compounds Sensitize Drug-Resistant Candida albicans Clinical Isolates to Fluconazole.Antimicrobial agents and chemotherapy · 2017Article
- Lactoferrin, chitosan and Melaleuca alternifolia-natural products that show promise in candidiasis treatment.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology]Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fungal infections represent a major burden in the critical care setting with increasing morbidity and mortality. Candidiasis is the leading cause of such infections, with C. albicans being the most common causative agent, followed by Aspergillosis and Mucormycosis. The diagnosis of such infections is cumbersome requiring increased clinical vigilance and extensive laboratory testing, including radiology, cultures, biopsies and other indirect methods. However, it is not uncommon for definitive evidence to be unavailable. Risk and host factors indicating the probability of infections may greatly help in the diagnostic approach. Timely and adequate intervention is important for their successful treatment. The available therapeutic armamentarium, although not very extensive, is effective with low resistance rates for the newer antifungal agents. However, timely and prudent use is necessary to maximize favorable outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.